Projects funded by the NCN
Identification of the mechanism of sensitization of human ovarian cancer cells to anticancer drugs by the DNA double strand breaks inhibitors
2016/23/N/NZ7/02023
Keywords:
ovarian cancer sensitization NHEJ HRR DNA repair inhibitors
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska
woj. łódzkie
Principal investigator (from the host institution):
Number of co-investigators in the project: 2
Call: PRELUDIUM 12 - announced on 2016-09-15
Amount awarded: 148 800 PLN
Project start date (Y-m-d): 2017-10-12
Project end date (Y-m-d): 2021-10-11
Project duration:: 48 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia ConditionsAuthors:Anna Macieja, Izabela Gulbas, Tomasz PopławskiAcademic press:Current Issues in Molecular Biology (rok: 2023, tom: 45(10), strony: 7915-7932), Wydawca: MDPI (Multidisciplinary Digital Publishing Institute)Status:PublishedDOI:10.3390/cimb45100500 - link to the publication